Indomethacin treatment of eighteen patients with Sweet's syndrome - 11/09/11
Abstract |
Background: |
The standard treatment for Sweet's syndrome (acute febrile neutrophilic dermatosis) is oral corticosteroids. Despite a good initial response, the disease is characterized by frequent relapses.
Objective: |
Our purpose was to test the therapeutic effect of the nonsteroidal antiinflammatory drug indomethacin on Sweet's syndrome.
Methods: |
All patients with Sweet's syndrome observed during a 4-year period were given indomethacm, 150 mg/day for the first week and 100 mg/day for two additional weeks. The therapeutic response was assessed on days 4, 7, 14, 30, and 180.
Results: |
Seventeen of 18 patients had a good initial response; fever and arthralgias were markedly attenuated within 48 hours and eruptions cleared between 7 and 14 days. The remaining patient's cutaneous lesions continued to develop and were successfully treated with prednisone (1 mg/kg/day). The only side effect of indomethacin treatment was epigastric pain in two patients. No patient had a relapse after discontinuation of indomethacin (mean follow-up, 20.1 months).
Conclusion: |
Indomethacin is a safe and effective treatment for Sweet's syndrome.
Le texte complet de cet article est disponible en PDF.
Vol 36 - N° 3
P. 436-439 - mars 1997 Retour au numéro
Article précédent
- Double-blind, placebo-controlled study of intralesional interferon gamma for the treatment of localized scleroderma
- Nicolas Hunzelmann, Sabine Anders, Gerhard Fierlbeck, Rüdiger Hein, Konrad Herrmalm, Manuela Albrecht, Sabine Bell, Rainer Muche, Jörg Wehner-Caroli, Wilhelm Gaus, Thomas Krieg
- Placement of the tension-bearing suture in repairing the alar facial junction
- June K. Robinson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?